Logo 1.png
Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million
February 16, 2021 22:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares
February 16, 2021 17:19 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
February 02, 2021 07:30 ET | Aeterna Zentaris Inc
- Company secures next step to continue to build-out pipeline of assets - University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing...
Logo 1.png
Aeterna Zentaris to Present at NobleCon17
January 15, 2021 08:05 ET | Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, January 20th at 12:00 PM ET – CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
LOGO.jpg
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
October 14, 2020 06:30 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET | Aeterna Zentaris Inc
- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...
Logo 1.png
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
September 08, 2020 08:05 ET | Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
August 03, 2020 09:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
OmniPathology-Logo-Color-01.jpg
OmniPathology Releases New COVID-19 Testing for Greater Los Angeles
March 24, 2020 14:42 ET | OmniPathology
PASADENA, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- OmniPathology today announced the launch of its COVID-19 Lab Developed Test LDT. In response to the US Food and Drug Administration (FDA) policy...